Challenging Research Models to Improve Health Equity

BioSpace

Diversity, equity and inclusion (DEI) continues to be a challenge for drug and medical device developers. While there has been some improvement in clinical trials, our guests note that unless there is a commercial or regulatory need, DEI is still an afterthought for many developers when designing clinical trials.

Host

⁠⁠⁠⁠⁠⁠⁠⁠⁠Lori Ellis⁠⁠⁠⁠⁠⁠⁠⁠⁠, Head of Insights, BioSpace

Guests

⁠⁠Ali Pashazadeh⁠⁠, CEO,Treehill Partners

Charlotte Jones-Burton, Board Member, bluebird bio; Founder & President, Women of Color in Pharma⁠⁠⁠

Chia Chia Sun⁠⁠⁠, Chief Commercial Officer, ⁠⁠⁠Fab Biopharma; CEO, Damiva

Phyllis Greenberger, Senior Vice President, Policy & Regulatory, Healthy Women

Todd Rudo, Chief Medical Officer, Clario

To listen to explicit episodes, sign in.

Stay up to date with this show

Sign in or sign up to follow shows, save episodes and get the latest updates.

Select a country or region

Africa, Middle East, and India

Asia Pacific

Europe

Latin America and the Caribbean

The United States and Canada